{"id":7056,"date":"2019-12-03T15:59:04","date_gmt":"2019-12-03T10:29:04","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7056"},"modified":"2023-01-05T09:59:52","modified_gmt":"2023-01-05T04:29:52","slug":"recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter","title":{"rendered":"\ufeffCumberland\u2019s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak\u2019s KSI-301; Sanofi offloads Seprafilm unit to Baxter"},"content":{"rendered":"\n

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. <\/strong><\/h3>\n\n\n\n

Cumberland pharmaceuticals pharma company focusing on acquiring and commercializing prescription products has gained access to the injection from Nordic Group two years back. Nordic\u2019s injectable methotrexate products manufactured to cure diseases, like active rheumatoid arthritis<\/a>, juvenile idiopathic arthritis<\/a>, severe psoriatic arthritis, and severe disabling psoriasis, have already been approved in Europe in 2016. <\/p>\n\n\n\n

With approval from the US FDA, Cumberland will gain the right to commercialize the product in the US. As per the agreement, Cumberland will proceed with the commercialization, marketing, branding, promoting, and distribution of the product line in the US. In return, Nordic will manufacture and receive payment upon achieving sales milestones. <\/p>\n\n\n\n

Injectable methotrexate-\nRediTrex<\/strong> is available in both oral and injectable forms. The oral form\nformulation is already available; however, the injection has been proved to be\nmore efficacious. Other marketed products of Cumberland pharmaceuticals include\nAcetadote<\/strong> injection, Caldolor<\/strong> injection, Kristalose<\/strong> oral\nsolution, and others. Moreover, the company also has an innovative pipeline of\nproducts such as Hepatoren<\/strong> injection, Boxaban<\/strong> oral capsule, Vasculan<\/strong>\nand other in its armamentarium. <\/p>\n\n\n\n

Kodiak Sciences\nfaces a spur of its shares as much as 146.5% higher after Baker Brothers\nAdvisors announced to enter into a financing partnership by investing a huge\namount of USD 225 Million for the rights to KSI-301.<\/strong><\/h3>\n\n\n\n

KSI-301 <\/strong>is an anti-VEGF antibody biopolymer conjugate therapy for the treatment of retinal vascular diseases, such as age-related macular degeneration (AMD)<\/a><\/strong> and diabetic eye diseases. <\/p>\n\n\n\n

Baker Brothers will have the royalty rights capped at 4.5% of the global sales of Kodiak\u2019s drug. Kodiak will receive an amount of USD 100 Million in the month of January 2020 upon the closure of the transaction. The remaining amount will be paid by Advisors after the achieving successful 50% enrolment of two planned the pivotal clinical studies of its drug in wet AMD patients, which were started in October. <\/p>\n\n\n\n

Moreover, the\nagreement underlines that the cap of the royalty of the Advisors will never\nexceed the 4.5%, however, the investors might take a stake in other follow-on\nproducts of KSI-301, in case the company decides to develop. <\/p>\n\n\n\n

During the whole\nperiod of the agreement, Kodiak retains the right to repurchase any portion of\nthe whole of the stake in its drug from Baker Bros. <\/p>\n\n\n\n

Sanofi has announced\nto trade off its unit Seprafilm Adhesion Barrier unit to Baxter International\nfor USD 350 Million. <\/strong><\/h3>\n\n\n\n

In a move to advance its surgery portfolio, Baxter has agreed to acquire Seprafilm, which will complement its leading hemostat and sealant portfolio for providing quality care to the patients in the operating unit. <\/p>\n\n\n\n

Seprafilm has been approved<\/a> to be used in abdominal or pelvic laparotomy (surgical incision into the abdominal or pelvic cavity). It is an adhesion barrier which acts as an adjunct to lower down the risk associated with postoperative adhesions between the abdominal wall and underlying viscera. <\/p>\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on acquiring and commercializing prescription products has gained access to the injection from Nordic Group two years back. Nordic\u2019s injectable methotrexate products manufactured to cure diseases, like active rheumatoid arthritis, […]<\/p>\n","protected":false},"author":1,"featured_media":7058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17865,17866,17863,1806,349,17864,639,5789,533],"industry":[17225],"therapeutic_areas":[17240,17227,17244],"class_list":["post-7056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-baker-brothers-advisors","tag-baxter-international","tag-cumberland-pharmaceuticals","tag-kodiak-sciences","tag-latest-pharma-news","tag-methotrexate","tag-pharma-news","tag-recent-pharma-news","tag-sanofi","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"\n\ufeffCumberland\u2019s methotrexate gets approval in the US<\/title>\n<meta name=\"description\" content=\"Kodiak Sciences faces a spur of its shares as much as 146.5% higher after Baker Brothers Advisors announced to enter into a financing partners...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffCumberland\u2019s methotrexate gets approval in the US\" \/>\n<meta property=\"og:description\" content=\"Kodiak Sciences faces a spur of its shares as much as 146.5% higher after Baker Brothers Advisors announced to enter into a financing partners...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-03T10:29:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-05T04:29:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/03155732\/News_03.12.2019.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\ufeffCumberland\u2019s methotrexate gets approval in the US","description":"Kodiak Sciences faces a spur of its shares as much as 146.5% higher after Baker Brothers Advisors announced to enter into a financing partners...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter","og_locale":"en_US","og_type":"article","og_title":"\ufeffCumberland\u2019s methotrexate gets approval in the US","og_description":"Kodiak Sciences faces a spur of its shares as much as 146.5% higher after Baker Brothers Advisors announced to enter into a financing partners...","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-12-03T10:29:04+00:00","article_modified_time":"2023-01-05T04:29:52+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/03155732\/News_03.12.2019.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter","name":"\ufeffCumberland\u2019s methotrexate gets approval in the US","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/03155732\/News_03.12.2019.jpg","datePublished":"2019-12-03T10:29:04+00:00","dateModified":"2023-01-05T04:29:52+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Kodiak Sciences faces a spur of its shares as much as 146.5% higher after Baker Brothers Advisors announced to enter into a financing partners...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-cumberland-baker-kodiak-sanofi-baxter#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/03155732\/News_03.12.2019.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/03155732\/News_03.12.2019.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/12\/03155732\/News_03.12.2019-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Baker Brothers Advisors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Baxter International<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cumberland Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kodiak Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Methotrexate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Baker Brothers Advisors<\/span>","<span class=\"advgb-post-tax-term\">Baxter International<\/span>","<span class=\"advgb-post-tax-term\">Cumberland Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Kodiak Sciences<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Methotrexate<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Dec 3, 2019","modified":"Updated on Jan 5, 2023"},"absolute_dates_time":{"created":"Posted on Dec 3, 2019 3:59 pm","modified":"Updated on Jan 5, 2023 9:59 am"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7056"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7058"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7056"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7056"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}